Start here if you're new
what it is
Eton buys, develops, and sells niche drugs for rare diseases that bigger pharma companies usually ignore.
how it gets paid
Last year Eton Pharma made $39M in revenue. metabolic portfolio was the main engine at $12M, or 31% of sales.
what just happened
Revenue hit $59M, but Eton still posted a loss.
At a glance
B balance sheet — gets the job done, barely
35/100 earnings predictability — expect surprises
-$0.15 fy2024 eps est
$39M fy2024 rev est
6.7% operating margin
xvary composite: 47/100 — below average
What they do
Eton buys, develops, and sells niche drugs for rare diseases that bigger pharma companies usually ignore.
Eton wins where big pharma does not bother showing up. It already sells 7 rare-disease drugs with just 31 employees, which means your competition is not another startup, it is corporate indifference. Rare disease focus means smaller patient pools but less crowding, so your shelf space and doctor attention can matter more.
How they make money
$39M
annual revenue
INCRELEX
$10M
ALKINDI SPRINKLE
$8M
GALZIN
$6M
metabolic portfolio
$12M
other commercial products
$3M
The products that matter
marketed rare-disease and hospital drugs
Commercial Products
$31M · 79.5% of revenue
This is the part of the business actually proving the model in cash terms. It generated $31M and grew 117% from a year ago, which is why the market is willing to look past current losses.
current engine
late-stage desmopressin candidate
ET-600
FDA date expected feb 25, 2026
There is no revenue attached to this asset in the current snapshot. It matters because a company valued at $508M on $39M of trailing sales needs approvals like this to keep the growth narrative intact.
binary catalyst
licensing and development economics
R&D & Licensing
$8M · 20.5% of revenue
This $8M bucket helps fund the story, but it is smaller and less durable than product revenue. If you want proof the business is scaling, Commercial Products matter more.
supporting revenue
Key numbers
113.0%
sales growth
Revenue more than doubled in the past period. Plain English: this is growing fast enough to hide a lot of flaws, until it does not.
$28M
long-term debt
Debt is 5% of capital. Plain English: the balance sheet is not the main problem here; execution is.
6.7%
operating margin
Operating margin means profit after running the business. Plain English: Eton is still losing money on the core operation.
$39M
annual revenue
This is still a small revenue base against a roughly $508M market cap, so your upside case needs more launches and better margins.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 10 / 100
- long-term debt $28M (5% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ETON right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $59M, but Eton still posted a loss.
Gross margin was 50.5%, which says the products have real economics. The problem is the company still reported EPS of -$0.23, so scale has not fully turned into profit yet.
$59M
revenue
-$0.23
eps
50.5%
gross margin
the number that mattered
$59M matters because it is larger than the full-year $39M figure cited elsewhere, which tells you Eton's reported growth is fast enough to make the data look almost broken.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The top threat is ET-600 delay or rejection. This is a $508M company with $39M in trailing revenue and no moat, so pipeline setbacks do not stay neatly contained.
med
ET-600 delay or rejection
The expected February 25, 2026 FDA decision is one of the clearest catalysts on the page. If it slips or fails, investors paying 13x sales lose one of the main reasons to look past current earnings losses.
Impact: this would pressure the premium multiple more than the current income statement, because the stock is priced on future launches.
med
commercial growth cools after the launch burst
Commercial Products grew 117% and now make up 79.5% of revenue. That is great. It also sets a hard comparison. If quarterly sales flatten after the recent jump, the market will notice fast.
Impact: when a $39M revenue business is valued at $508M, slower product revenue can compress the stock even without a balance-sheet crisis.
med
patent and commercialization litigation
The annual filing cites patent-infringement risk. For a small pharma, legal fights are not just expensive. They can delay launches, change economics, and absorb management attention the business cannot easily spare.
Impact: even if revenue stays intact, legal costs can eat into a business that is only earning a 50.5% gross margin and still posting negative EPS.
med
thin float and reversible institutional flow
Institutional ownership is 27.9%. The page also shows 74 institutions bought over the last year and $67.1M of inflows, but that support can reverse. One holder already cut its stake by 40%.
Impact: with price stability at 10 / 100, ownership shifts can move the stock harder than fundamentals in the short run.
At $508M of market value against $39M of trailing revenue, this stock has very little room for a bad regulatory surprise or a stalled commercial ramp.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
ET-600 FDA decision
Expected by February 25, 2026. This is the cleanest binary event on the page and one of the biggest reasons the stock carries a premium sales multiple.
revenue
commercial products pace
Commercial Products generated $31M and 79.5% of total revenue. If that mix keeps rising, the story gets more investable and less speculative.
earnings
march 19 results
The next report needs to show the recent $17.3M quarter was not just launch noise. One quarter starts a story. Two quarters make it harder to dismiss.
ownership
institutional flow reversals
There were 74 institutional buyers and $67.1M of inflows over the last year, but one major holder trimmed by 40%. In a volatile small cap, that matters more than usual.
Analyst rankings
earnings predictability
35 / 100
Low predictability means estimates move around a lot. In human-speak, analysts do not have a stable earnings machine to model here.
risk rank
3
This sits around the middle of the pack. Not a balance-sheet disaster, not a defensive stock either.
price stability
10 / 100
The shares have been volatile. That fits a company driven by approvals, launches, and sentiment more than slow-and-steady compounding.
source: institutional data
Institutional activity
institutional ownership data for ETON is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$18
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive